{"id":574918,"date":"2021-11-15T18:02:01","date_gmt":"2021-11-15T18:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=574918"},"modified":"2021-11-15T18:02:01","modified_gmt":"2021-11-15T18:02:01","slug":"intratumoral-cancer-therapies-market-scenario-insights-and-emerging-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/intratumoral-cancer-therapies-market-scenario-insights-and-emerging-therapies-delveinsight_574918.html","title":{"rendered":"Intratumoral Cancer Therapies Market Scenario, Insights, and Emerging Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1636957405.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Intratumoral Cancer Therapies Market Scenario, Insights, and Emerging Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1636957405.jpeg\" alt=\"Intratumoral Cancer Therapies Market Scenario, Insights, and Emerging Therapies | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">A detailed review of the forecasted <strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Intra-tumoral Cancer Therapy market<\/a><\/span><\/strong> is included in the report, covering its outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Intra-tumoral Cancer Therapy market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Intratumoral immunotherapy\/ cancer therapy is a therapeutic strategy that aims to use the tumor as its own vaccine. It is a revolutionary cancer treatment that makes use of sophisticated antibodies, which are directly injected into the cancer tumors, instead of intravenously.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download sample report- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Intratumoral Cancer Therapies Market Report<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights of the Intratumoral Cancer Therapies market report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cancer of the skin is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths.&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li>About 106,110 new melanomas will be diagnosed (about 62,260 in men and 43,850 in women).<\/li>\n<li>HCC is the dominant type of liver cancer, accounting for approximately 75% of the total.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Intratumoral Cancer Therapies Market Companies<\/strong><\/a><\/span><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Daiichi Sankyo<\/li>\n<li>Amgen<\/li>\n<li>Idera Pharmaceuticals<\/li>\n<li>Philogen<\/li>\n<li>Oncolys BioPharma<\/li>\n<li>Highlight Therapeutics<\/li>\n<li>And many others<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">Currently, only three intratumoral therapies are approved; Imlygic (Talimogene laherparepvec\/T-VEC; Amgen), the first oncolytic virus that was approved by the US FDA for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery in 2015. Later, in April 2020, the EU granted approval (CE mark) to Hensify (NBTXR3; Nanobiotix) for the treatment of locally advanced soft tissue sarcoma (STS), however it is not launched yet. Recently, in June 2021, Delytact (teserpaturev\/G47\u2206; Daiichi Sankyo) received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with malignant glioma The emerging pipeline is majorly focused on the treatment of melanoma, head and neck cancer, Nonmelanoma skin cancer, along with some other cancers and expectations are high from Intratumoral Cancer Therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Intratumoral Cancer Therapies Drugs<\/strong><\/a><\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>Delytact (teserpaturev\/G47\u2206\/ DS-1647): Daiichi Sankyo<\/li>\n<li>Imlygic (Talimogene laherparepvec; T-VEC): Amgen<\/li>\n<li>Hensify (NBTXR3\/ PEP503): Nanobiotix<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vidutolimod (CMP-001): Checkmate Pharmaceuticals<\/li>\n<li>Tavokinogene telseplasmid (Tavo): OncoSec Medical Incorporated<\/li>\n<li>RP1 (Vusolimogene Oderparepvec): Replimune<\/li>\n<li>INT230-6 (Cisplatin\/vinblastine): Intensity Therapeutics<\/li>\n<li>NanoPac (LSAM Paclitaxel): NanOlogy<\/li>\n<li>LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB<\/li>\n<li>Intuvax (Ilixadencel): Immunicum AB<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Emerging Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intuvax (Ilixadencel): Immunicum AB<\/li>\n<li>PV-10<\/li>\n<li>Vidutolimod<\/li>\n<li>Pexa-vec<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request sample report- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Intratumoral Cancer Therapies Market Outlook<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Intratumoral cancer therapies Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Key Highlights from Report<\/p>\n<p style=\"text-align: justify;\">5. Executive Summary of Intratumoral cancer therapy<\/p>\n<p style=\"text-align: justify;\">6. Epidemiology and Market Forecast Flow<\/p>\n<p style=\"text-align: justify;\">7. Background and Overview<\/p>\n<p style=\"text-align: justify;\">8. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">9. Key Endpoints in Intratumoral cancer therapies<\/p>\n<p style=\"text-align: justify;\">10. Marketed Therapies<\/p>\n<p style=\"text-align: justify;\">11. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Intratumoral Cancer Therapies: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">13. Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers<\/p>\n<p style=\"text-align: justify;\">15. Market Barriers<\/p>\n<p style=\"text-align: justify;\">16. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">17. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Appendix<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\">Yash<\/p>\n<p style=\"text-align: justify;\">info@delveinsight.com<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=intratumoral-cancer-therapies-market-scenario-insights-and-emerging-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=intratumoral-cancer-therapies-market-scenario-insights-and-emerging-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A detailed review of the forecasted Intra-tumoral Cancer Therapy market is included in the report, covering its outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Intra-tumoral &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/intratumoral-cancer-therapies-market-scenario-insights-and-emerging-therapies-delveinsight_574918.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-574918","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/574918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=574918"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/574918\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=574918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=574918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=574918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}